Want to see OABI full AI Analyst Report?
OABI Stock Chart & Stats
$1.97
-$0.01(-0.51%)
At close: 4:00 PM EDT
$1.97
-$0.01(-0.51%)
Day’s Range― - ―
52-Week Range$1.30 - $4.71
Previous CloseN/A
Volume186.59K
Average Volume (3M)561.73K
Market Cap
$629.54M
Enterprise Value$283.75
Total Cash (Recent Filing)$51.99M
Total Debt (Recent Filing)$18.91M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 17, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding145,390,400
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.79
Price to Sales (P/S)11.26
P/FCF Ratio-5.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside306.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$34.93M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceRapid revenue growth and higher full-year guidance indicate stronger monetization of partner milestones and services. If sustained, this trajectory can improve operating leverage and demonstrate increasing demand for OmniAb’s discovery platforms.
Broad Partner And Program NetworkA large, diversified partner and program base creates multiple opportunities for future milestones and royalties, reducing reliance on any single collaboration. Contracted downstream economics also provide durable participation in partner program success.
Contracted Milestone And Royalty PotentialThe contracted milestone and royalty portfolio provides meaningful long-term economic leverage to partner development and commercialization. Clinical-stage programs with approximately $340M of remaining milestones add visibility to future value creation.
Bears Say
Persistent Losses And Cash BurnOmniAb remains structurally unprofitable and is funding operations with balance-sheet resources rather than internally generated cash. Continued losses and negative free cash flow could constrain investment, increase financing needs, and dilute the benefit of revenue growth.
Milestone Revenue DependenceRevenue tied to partner milestones is inherently uneven and dependent on external clinical, regulatory, and development decisions. This limits earnings visibility and can make sustainable growth difficult to assess even when the underlying partner portfolio expands.
Early XPloration CommercializationThe instrument business has not yet established recurring commercial scale, leaving its contribution uncertain. Execution must progress from initial placements to repeat consumables, software, and service revenue before xPloration can materially diversify OmniAb’s economics.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.30 and its highest was $4.71 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $629.54M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Aug 06, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.07.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.13.
How many shares outstanding does OmniAb have?
OmniAb has 145,390,400 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went up 37.5%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OmniAb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (306.09% Upside)
$8.00 (306.09% Upside)
Blogger Sentiment
Bearish
OABI Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 180.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.83%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial year-over-year revenue growth (~244% for Q2 and ~243% YTD), marked improvement in net losses (~60%+ reduction), upgraded full-year revenue and cash guidance, expanding partner/program base, and notable clinical progression including two programs advancing rapidly to Phase III. Risks highlighted include the lumpiness of milestone-driven revenue, an early-stage xPloration commercialization ramp, ongoing (though reduced) GAAP losses, and dependence on partner development timelines for future royalties. On balance, positive execution and meaningful clinical/contracted upside appear to outweigh the near-term variability and commercialization risks.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$8.00
▲(306.09% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.85% Insiders
9.87% Mutual Funds
16.10% Other Institutional Investors
59.57% Public Companies and
Individual Investors